Lawmakers ask FTC for retrospective review of PBM mergers

Greg Walden speaks during hearing
Rep. Greg Walden (R-Ore.) was one of three lawmakers that requested the FTC conduct a retrospective review of PBM mergers. (Getty/pabradyphoto)

Leaders of the House Energy and Commerce Committee have requested the Federal Trade Commission (FTC) to determine whether three mergers among the industry's largest pharmacy benefit managers have brought down healthcare costs.

In a letter (PDF) to FTC Commissioner Joseph Simons, Reps. Greg Walden (R-Ore.), Michael Burgess, M.D. (R-Tex.) and Gregg Harper (R-Miss.) requested the agency conduct a retrospective analysis of consolidation among pharmacy benefit managers to measure the effectiveness of past enforcement and the impact on downstream healthcare costs.

The three largest PBMs—UnitedHealthcare’s Optum Rx, CVS Caremark and Express Scripts—accounted for 70% of market revenues in 2016, in part because of several significant mergers over the last decade. CVS Health bought Caremark in 2007, Express Scripts bought Medco Health Solutions in 2012 and UnitedHealth bought Catamaran in 2015.

Free Daily Newsletter

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

RELATED: In a blow to PBMs, Trump administration mulling overhaul to drug rebate safe harbor protections

Those three mergers were worth $68.3 billion combined.

Two of those companies are currently seeking regulatory approval for several vertical mergers, with CVS buying Aetna for $69 billion and Cigna purchasing Express Scripts for $67 billion.

But the lawmakers pointed to conflicting information about their impact, including some research that shows PBMs may have used their market power to encourage higher list prices, increasing patient copays. During a February hearing before the committee, policy experts suggested a retrospective analysis would help solidify answers to lingering questions about PBMs.

RELATED: Senators press PBMs to clarify Azar's ‘extremely disturbing' drug pricing allegations

“The Commission believes that the FTC should conduct a retrospective review of past PBM merger to help improve our understanding of the impact of consolidation in the PBM industry and whether past enforcement has been effective,” the lawmakers wrote.

Simons also previously told lawmakers he hoped to establish a retrospective program to analyze merger enforcement, including in the PBM industry. The lawmakers asked Simons to confirm the agency plans to conduct the study by Aug. 10.

Suggested Articles

Centene Corporation posted $95 million in profit for the third quarter of 2019, which skyrocketed from $19 million in the third quarter of 2018.

A KHN investigation found that manufacturers, hospitals, doctors and some patient advocates have put marketing muscle behind 3D mammograms.

Benchmark premiums for plans on are down 4% for the 2020 plan year, the Trump administration announced Tuesday.